2017, Volume 19, Issue 2
Strategic Study of CAE >> 2017, Volume 19, Issue 2 doi: 10.15302/J-SSCAE-2017.02.010
Concepts for the Construction of a New National Drug Service System
1. National Pharmaceutical Engineering Research Center, Shanghai 201203, China;
2. West China School of Pharmacy, Sichuan University, Chengdu 610041, China;
3. School of Pharmaceutical Sciences, Peking University, 100191, China;
4. Shanghai Institute for Food and Drug Control, Shanghai 201203, China;
5. Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China;
6. Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
Next Previous
Abstract
Although the current drug service system can meet the fundamental needs of healthcare in China, outstanding issues exist in all service sectors, including research and development, manufacturing, marketing, and clinical use. Through a literature search, data queries, specialist consultation, and a panel discussion, this study investigated the current status of the drug service system and identified the main problems. We propose an idea for constructing a new national drug service system to provide drugs to the Chinese people that are of high quality, have a reliable therapeutic effect, come at a reasonable price, and exhibit good medical compliance, thus ensuring the efficacy, safety, availability, and reasonability of drugs for clinical use, as well as promoting a structural transformation of the pharmaceutical industry that will enable China to finally transition from a big country into a great power in the global pharmaceutical industry.
Keywords
drug ; service system ; pharmaceutical industry ; supervision ; development strategy
References
[ 1 ] Fan D M. Health care reform: Addition, subtraction, multiplication and division [J]. Negative, 2016, 7(3): 1–20. Chinese.
[ 2 ] Ministry of Industry and Information Technology of the People’s Republic of China, National Development and Reform Com-mission of the People’s Republic of China, Ministry of Science and Technology of the People’s Republic of China, Ministry of Commerce of the People’s Republic of China, National Health and Family Planning Commission of the People’s Republic of China, China Food and Drug Administration of the People’s Republic of China. Notice on issuing guide for development of pharmaceutical industry [EB/OL]. (2016-10-16) [2016-11-07]. http://www.miit.gov. cn /n1146295/ n1146592/n3917132/n4061512/c5343399/con-tent. html. Chinese.
[ 3 ] Yang M C, Wang L B, Lin M, et al. Research on analysis of quality difference and risk control between domestic and imported drugs [J]. Shanghai Food and Drug Information Research, 2011, 12(6): 33–45. Chinese.
[ 4 ] Drug Registration Division of China Food and Drug Adminis-tration of the People’s Republic of China. Drafting instruction of the work plan for evaluation of the quality consistency of generic drugs (Draft) [EB/OL]. (2012-11-22) [2016-11-15]. http://www.sda.gov.cn /wso1/CL0778/76295.html. Chinese.
[ 5 ] Wang X L, Guo C Y. Analysis of present situation of pediatric drug formulation and specifications in foreign countries [J]. Chinese Pharmaceutical Journal, 2013, 48(17): 1317–1320. Chinese.
[ 6 ] Chen Q, Du G. The present situation and the management strategy of pediatric drug dosage forms [J]. Journal of Pediatric Pharmacy, 2013, 19(8): 49–52. Chinese.
[ 7 ] Delgado-Charro M B, Guy R H. Effective use of transdermal drug delivery in children [J]. Advanced Drug Delivery Reviews, 2014, 73: 63–82. link1
[ 8 ] Kuang L C, Feng G Z. Analysis on the development status of Chi-nese pharmaceutical industry [J]. Modern Business Trade Industry, 2015(10): 7–9. Chinese.
京公网安备 11010502051620号
